Hyponatremia Clinical Trial
Official title:
Comparison of the Vasopressin-2 Antagonist Tolvaptan and Fluid Restriction in the Treatment of Hyponatremia Following Pituitary Surgery
NCT number | NCT04119206 |
Other study ID # | Tolvaptan |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2009 |
Est. completion date | December 31, 2013 |
Verified date | October 2019 |
Source | University of Erlangen-Nürnberg Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Context. The relevance of hyponatremia has been acknowledged by guidelines from the United
States of America (2013) and Europe (2014). However, treatment recommendations differ due to
limited evidence.
Objective. In hyponatremia following pituitary surgery - caused by the syndrome of
inappropriate antidiuretic hormone (SIADH) secretion - the investigators compared fluid
restriction with the pharmacological increase of water excretion by blocking the vasopressin
2 receptors with tolvaptan at a low and moderate dose.
Design. Prospective observational study.
Setting. Neurosurgical Department of a University hospital with more 200 pituitary procedures
per year.
Patients. Participants undergoing surgery for sellar lesions and developing a serum sodium
below 135 mmol/L. The diagnosis of SIADH was established by eu- or hypervolemia (daily
measurement of body weight and fluid balance daily), an inappropriately concentrated urine
(specific gravity) and exclusion of a cortico- and thyreotropic insufficiency.
Intervention. Participants were treated with fluid restriction (n=38) or tolvaptan at 3.75
(n=38) or 7.5 mg (n=48) orally.
Main Outcome Measures. Treatment efficacy was assessed by the duration of hyponatremia,
sodium nadir and length of hospitalization. Safety was established by an increment serum
sodium below 10 mmol/L per day and exclusion of side effects.
Status | Completed |
Enrollment | 334 |
Est. completion date | December 31, 2013 |
Est. primary completion date | December 31, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Informed written consent was given by the participant or the next-of-kin. Exclusion Criteria: Age below 18 years Pregnancy Tolvaptan intolerance. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Erlangen-Nürnberg Medical School |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean serum sodium concentration | Postoperative mean serum sodium | Day 1 post-op up to 15 days | |
Primary | Serum sodium nadir concentration | Postoperative serum sodium nadir | Day 1 post-op up to 15 days | |
Primary | Number of days with serum sodium concentration below 136mmol/L | No. of postoperative days serum sodium was below 136mmol/L | Day 1 post-op up to 15 days | |
Primary | Number of days with serum sodium concentration below 133mmol/L | No. of postoperative days serum sodium was below 133mmol/L | Day 1 post-op up to 15 days | |
Secondary | Number of events with mild serum sodium overcorrection | Serum sodium overcorrection > 5mmol/L*24hrs | Day 1 post-op up to 15 days | |
Secondary | Number of events with severe serum sodium overcorrection | Serum sodium overcorrection > 10mmol/L*24hrs | Day 1 post-op up to 15 days | |
Secondary | Number of days in the hospital | Duration of hospital stay | Up to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06037928 -
Plasma Sodium and Sodium Administration in the ICU
|
||
Recruiting |
NCT04561531 -
Efficacy and Safety of Bolus Comparing With Continuous Drip of 3% NaCl in Patients With Severe Symptomatic Hyponatremia.
|
N/A | |
Terminated |
NCT02012959 -
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
|
Phase 3 | |
Recruiting |
NCT02936167 -
Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children
|
N/A | |
Completed |
NCT00621348 -
Maintenance Intravenous Fluids in Children
|
Phase 3 | |
Terminated |
NCT03703713 -
Colloid Osmotic Pressure and Osmolality in Hyponatremia
|
||
Completed |
NCT02926989 -
Intravenous Fluids in Hospitalised Children
|
Phase 4 | |
Terminated |
NCT02959411 -
Tolvaptan for Advanced or Refractory Heart Failure
|
Phase 4 | |
Completed |
NCT02573077 -
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
|
||
Withdrawn |
NCT02667977 -
Reexamining Hypotonic Intravenous Fluid Use
|
N/A | |
Terminated |
NCT01708811 -
Hyponatremia and Myometrium Contractility. An Invitro Study
|
N/A | |
Withdrawn |
NCT01326429 -
Frequency and Origin of Dysnatremias in the Emergency Department
|
N/A | |
Completed |
NCT01456533 -
Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients
|
N/A | |
Terminated |
NCT01227512 -
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
|
Phase 3 | |
Recruiting |
NCT06013800 -
Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
|
||
Terminated |
NCT04020926 -
Impact of Hyponatremia on Muscle Strength, Gait and Cognitive Function
|
||
Completed |
NCT02545101 -
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
|
N/A | |
Withdrawn |
NCT02442674 -
A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
|
Phase 3 | |
Terminated |
NCT02215148 -
Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients
|
N/A | |
Recruiting |
NCT01748331 -
The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia
|
N/A |